|
|
||||||||
J Thorac Cardiovasc Surg 2002;123:288-294
© 2002 The American Association for Thoracic Surgery
General Thoracic Surgery (GTS) |
From the Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia Health System, Charlottesville, Va.
Supported by National Institutes of Health grants RO1 HL48242 and T32 HL07849. Additional support from the National Institute of Child Health and Human Development and the National Institutes of Health through cooperative agreement U54 HD28934.
Received for publication May 14, 2001. Revisions requested July 11, 2001; revisions received July 30, 2001. Accepted for publication Aug 2, 2001. Address for reprints: Victor Laubach, PhD, University of Virginia Health System, Department of Surgery, PO Box 801359, Charlottesville, VA 22908-1359 (E-mail: vel8n{at}virginia.edu).
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
| Material and methods |
|---|
|
|
|---|
Left upper lobectomy procedure
Swine were anesthetized with an intramuscular tiletamine and zolazepam (Telazol) and xylazine mixture. The animals underwent endotracheal intubation and continuous anesthesia with 1% to 2% inhalational halothane. A left posterolateral thoracotomy was performed, and the hemiazygous vein was divided to enhance exposure of the left hilum. The inferior pulmonary ligament was divided to the level of the inferior pulmonary vein. After the intravenous administration of heparin sodium (200 U/kg), the pulmonary venous and arterial branches to the left upper lobe were individually ligated and divided. The bronchus to the left upper lobe was then ligated and divided, with care not to encroach upon the LLL bronchus. Finally, the fissure between the left upper and lower lobes was sharply divided to complete the left upper lobectomy in this group. A chest tube was placed to underwater suction drainage, and the chest was closed in layers. At the completion of the procedure 0.25% bupivacaine hydrochloride (Sensorcaine) was used for an intercostal nerve block.
For the LLL harvest procedure, immediately on completion of a left upper lobectomy as described previously, 30 µg prostaglandin E1 was infused into the left pulmonary artery. The main pulmonary artery was then clamped, and a 16-gauge angiocatheter was inserted distally with its tip directed into the left pulmonary artery. After venting of the heart through a left atriotomy, 1 L Euro-Collins preservation solution at 4°C was infused from a height of 30 cm. Room air ventilation was continued throughout the flush period. Topical cooling of the LLL was achieved with cold saline slush. The LLL was then rapidly excised and prepared on the back table for implantation.
Recipient left pneumonectomy and LLL implantation
The techniques of recipient pneumonectomy and LLL implantation have been previously described elsewhere by our laboratory.
2 With the animal under 1% to 2% inhalational halothane anesthesia, a posterolateral thoracotomy was performed. After the intravenous administration of heparin sodium (200 U/kg), the left lung was removed.
After preparation and weighing of the mature donor LLL, the implantation procedure began. The bronchial anastomosis was performed first with a continuous 4-0 polypropylene suture. To compensate for the size disparity between the large donor LLL bronchus and the smaller recipient left main stem bronchus, the latter was telescoped into the former for a distance of approximately 0.5 cm. To test for air leaks, the completed airway anastomosis was immersed in saline solution while the LLL was ventilated at high pressures. The pulmonary arterial anastomosis was then performed with a continuous 5-0 polypropylene suture. Finally, the donor left atrial cuff was anastomosed to the recipient left atrial appendage with a continuous 5-0 polypropylene suture. Tube thoracostomy, intercostal nerve block, and chest closure were all performed in the same manner as described previously. Although chest closure was challenging in all transplant recipients because of marked size disparities between the voluminous donor lobes and the small recipient left hemithoraces, pneumoreduction procedures did not prove necessary.
All animals received humane care in accordance with the "Guide for the Care and Use of Laboratory Animals" prepared by the Institute of Laboratory Animal Resources, National Research Council, and published by the National Academy Press, revised 1996. The protocol described here was approved by the animal review committee of the University of Virginia.
Removal for study of LLL tissue
Animals in the transplantation, lobectomy, and normal control groups received intravenous injections of 5-bromo-2'-deoxyuridine (BrdU, 50 mg/kg; Sigma, St Louis, Mo) 16 hours before the time designated for LLL excision. This agent facilitated the later identification of proliferating cells by the technique described here (BrdU immunohistochemical staining). Animals were then anesthetized with intravenously administered sodium pentobarbital and weighed while undergoing room air endotracheal ventilation. Through a left posterolateral thoracotomy, the LLL was dissected free of adhesions within the left hemithorax. After lethal injection of sodium pentobarbital and exsanguination through a left atriotomy, the LLL was rapidly excised and weighed. A small peripheral portion of the LLL was clamped, and a sample of fresh lung tissue was excised and frozen for subsequent determination of wet to dry weight ratios and molecular analyses. The remainder of the lung tissue was fixed through intrabronchial instillation of 70% ethanol from a height of 25 cm. At the completion of the fixation process, the bronchus was clamped and the lobe was stored inflated at 4°C in 70% ethanol for 24 hours. Fixed tissue was then embedded in paraffin and used for morphometric and cell proliferation analyses.
Morphometric analysis
Approximately 10 peripheral tissue blocks (1 cm3 each) were prepared by random sampling of fixed lung tissue. Tissue blocks were embedded in paraffin, and 5-µm sections were stained with hematoxylin and eosin. Morphometric analysis was then performed in a manner similar to that of Davies
11 and Wandel and colleagues.
12 Each tissue section was examined under a Nikon Eclipse E400 microscope (Nikon Inc, Melville, NY) equipped with an eyepiece reticule containing a 42-point test lattice with 85-µm grid line lengths. By systematically selecting every third microscopic field, at least 4 fields were analyzed for each section. The first analysis was performed under 40 times magnification and consisted of counting all points falling on intra-acinar air spaces or intervening alveolar walls or septa (Pr). The percentage volume of respiratory region (Vvr) was then calculated from the equation Vvr = (Pr/Pp) x 100%, where Pp was the total number of test points per field (42). Because Vvr includes the volume density of alveolar air spaces, duct spaces, and septal tissue, this parameter represents the percentage of peripheral lung composed of gas-exchanging parenchyma. It therefore excludes nonparenchymal tissues such as conducting airways and vasculature.
At 200 times magnification the number of grid lines intercepting the airspace-epithelial interface (Is) was counted. From this value the alveolar surface density (Sv) could be calculated as Sv = (2/d) x (Is/Pp), where d was the length of each test grid line (85 µm) and Sv represents the alveolar surface area in square centimeters per cubic centimeter of peripheral lung.
BrdU immunohistochemical study
BrdU is a thymidine analog that is incorporated into replicating DNA during the S phase of the cell cycle. This molecule has been adopted as a marker for cellular proliferation
13 and has become a valuable research tool for studies of pneumocyte proliferation and lung growth. Peripheral lung sections were incubated with anti-BrdU monoclonal antibody (1:100; DAKO Corporation, Carpinteria, Calif). Immunohistochemical detection of BrdU-labeled nuclei was facilitated by the alkaline phosphatase system (VectaStain ABC-AP kit; Vector Laboratories, Inc, Burlingame, Calif). A nuclear fast red counterstain was used to discern nonreplicating nuclei. Examining the tissue sections under light microscopy, both BrdU-labeled and unlabeled nuclei were counted in a systematic fashion. For each animal at least 500 nuclei were counted from cells comprising the gas-exchange compartment (alveolar wall cells lining the alveolar airspaces). Nuclei in the immediate vicinity of conducting airways and vasculature were excluded from the analysis. Results were expressed as the alveolar cell proliferation index (CPI), defined as the percentage of nuclei labeled with BrdU.
Western blot analysis of epidermal growth factor receptor
Peripheral lung samples (0.25 g) were homogenized in 50-mmol/L tris(hydroxymethyl)aminomethane (Tris) hydrochloride, pH 7.4, 0.1-mmol/L ethylenediaminetetraacetic acid, 0.1-mmol/L ethyleneglycol-bis-(ß-aminoethylether)-N,N,N',N'-tetraacetic acid, 1-mmol/L phenylmethylsulfonyl fluoride, 4-µg/mL pepstatin A, 4-µg/mL leupeptin, and 0.1% 2-mercaptoethanol and were centrifuged at 4°C at 5000 rpm. Protein concentrations were determined with Coomassie Plus Protein Assay Reagent (Pierce Chemical Company, Rockford, Ill). Purified lung protein (125 µg) was fractionated on a denaturing 7.5% polyacrylamide gel and subsequently transferred to nitrocellulose. The blot was incubated with primary antibody to epidermal growth factor receptor (EGFR, 1 µg/mL; Santa Cruz Biotechnology, Inc, Santa Cruz, Calif) for 2 hours at room temperature. This was then washed with 50-mmol/L Tris hydrochloride, pH 7.4, 150-mmol/L sodium chloride, and 0.1% 20-polysorbate and was incubated for 1 hour with secondary antibody coupled to horseradish peroxidase.
After a second washing, protein bands were identified by chemiluminescence (ECL; Amersham Pharmacia Biotech, Inc, Piscataway, NJ) and quantitated by computerized densitometry (Alpha Imager 2000; Alpha Innotech Corporation, San Leandro, Calif). The units for quantitation of bands on Western blot are relative density units, not absolute numbers, and thus one cannot directly compare data from separate figures. EGFR protein was confirmed by its known molecular weight of 170 kd
14 and also by Western blot analysis of EGFR expression in A431 human carcinoma cells (not shown).
Statistical analysis
Analysis of variance and the Bonferroni multiple comparison test were used to determine statistically significant differences among the three groups. When only two values were compared, a paired samples test was employed. Measurements are reported as mean ± SEM.
| Results |
|---|
|
|
|---|
|
Alveolar CPI
The alveolar CPI was determined with BrdU immunostaining. The lobectomy group exhibited a statistically significant increase in alveolar CPI at 2 weeks, with a return to baseline levels by 3 months (Figure 2). In contrast, the transplanted lobe exhibited a slower increase in CPI, reaching a statistically significant increase relative to normal control and lobectomy groups at 3 months(Figure 2
).
|
|
|
|
| Discussion |
|---|
|
|
|---|
In our experiments compensatory lung growth after lobectomy was seen as a rapid process that reached statistical significance at 2 weeks, as illustrated by the gain in lobar weight. This growth was sustained at the 3-month interval. Posttransplantation lung growth, on the other hand, was seen as a gradual process that approached statistical significance at 3 months. To determine whether this increase in lobar weight was true growth, wet to dry ratios were determined to rule out edema as a cause of the increased weight. These ratios were similar among all groups (5.6 ± 0.1, 5.6 ± 0.3, and 5.9 ± 0.5 for normal control, transplantation, and lobectomy groups, respectively, difference not statistically significant); we thus can conclude that this gain in lobar weight was indeed tissue growth and that edema was not a contributing factor. We can postulate various reasons for the differences in growth during each of these processes. Free space in the thorax after lobectomy could explain the more rapid growth in the compensatory growth process, and possible ischemia-reperfusion injury in the transplantation group could serve as a stimulus for cytokine and growth factor production, which could be an additional method of growth stimulation.
We terminated our study at the 3-month time point because this was a long enough period to observe long-term growth while preventing unnecessary costs of prolonged animal housing. In addition, we wanted the study to be consistent with our previous studies, which also used the 3-month postsurgical growth period. We predict that continued lung growth would be observed on longer follow-up times, at least in the transplantation group. We did not conduct any lung function analysis in this study; however, previous studies by our laboratory have demonstrated that mature lobar transplantation, when compared to lobectomy, resulted in no statistically significant differences in functional residual capacity, wet to dry weight ratios, or oxygenation.
2,3
The next thing we wanted to examine was the mitogenic response in the lung during each of these growth processes. We measured this property with BrdU immunostaining techniques for proliferating alveolar cells in the lung. Compensatory lung growth exhibited a statistically significant increase in CPI at the 2-week interval, with a return to baseline levels at 3 months. Posttransplantation lung growth on the other hand, exhibited a gradual increase in CPI, reaching statistical significance at 3 months. This further indicates that compensatory lung growth is a rapid process, whereas posttransplantation lung growth represents a more gradual process. Once again, it is important to realize the constraints on posttransplantation lung growth in our model, including the issue of free space in the thorax. The transplanted lungs fit snugly in the left hemithoracic space, and this may have hindered rapid growth of these lungs.
Morphometric techniques were used to calculate Vvr, which represents the percentage of peripheral lung that is occupied by alveoli and interalveolar tissue. Only the transplanted lobe exhibited an increase in Vvr at 3 months. It is important to realize that even though the compensatory growth process did not appear to increase Vvr, we can conclude that the overall compartment in the lung did increase because the total amount of lobar tissue (as measured by weight) increased statistically significantly. Another morphometric parameter that we measured was alveolar surface density (Sv), which represents the alveolar surface area per unit volume of peripheral lung tissue. This parameter was constant in both postlobectomy and posttransplantation lung growth. The microscopic architecture of the alveoli was preserved in both these growth processes regardless of the time interval, and the alveoli in neither process exhibited hyperinflation or distension. Once again because of the increase in lobar tissue, we can infer that the total number of alveoli increased in the compensatory growth process at 2 weeks and in the posttransplantation growth process at 3 months.
Measurement of Vvr and Sv is not a simple technique, and interpretation of morphometric data can be even more perplexing. Sv is an indicator of the complexity of alveolar structure. Because we observed normal lung architecture in all the groups, any changes in Sv were most likely due to changes in alveolar size (decreased alveolar size would lead to increased Sv and vice versa). As indicated inFigure 3
, we found no statistically significant differences in Sv among any of the groups, but we did find a statistically significant increase in Vvr in the transplantation group. By evaluating the lobe weight, Sv, and Vvr data together in the transplantation group, the increase in Vvr with constant Sv indicates that the increase in lung tissue (weight) most likely occurred through increase in the number of alveoli, especially because normal lung architecture was maintained.
The relationship between Vvr and Sv is difficult to ascertain. Rapid growth of the lung resulting in increased Vvr could be explained by decreased alveolar size (decreased Sv) and could indicate that the new alveoli were growing by budding or sprouting from existing alveolar sacs. However, the mechanisms of alveolar growth after lobectomy and transplantation are not known. The morphometric measurements that we conducted do not allow us to determine the method of alveolar growth or structure, and further studies will be necessary to determine this. Increased Vvr could also occur by alveolar hypertrophy. In addition, we looked at only two time points (2 weeks and 3 months), and it is possible that peak periods of rapid alveolar growth occurred at a time point that was not evaluated in our study. Unfortunately, the expense of the pig transplantation model precludes us from testing many time points.
Circulating growth factors are important stimuli for growth. We focused on EGFR expression because epidermal growth factor (EGF) has been shown to play an important role in pulmonary morphogenesis and type II pneumocyte proliferation.
15,16 Comparing the normal control group with the lobectomy group, we observed an upward regulation of EGFR at 2 weeks after lobectomy, which returned to baseline at 3 months. Next we compared how the lobectomy and transplantation groups compared with the normal control group at 3 months. We observed that the transplanted lobes exhibited an upward regulation of EGFR at 3 months when compared with the lobectomy and normal control groups. The upward regulation of EGFR in both models coincided with the time that statistically significant growth was apparent in terms of increased CPI. Although we have not shown any causal relationship between EGF and lung growth, we did show in another study that the administration of EGF stimulates post-pneumonectomy lung growth.
17 In that study we noted that EGF administration correlated with upward regulation of EGFR. This association between lung growth and EGFR upward regulation in both posttransplantation and compensatory growth processes could represent a novel avenue for the modulation of adult lung growth. Future studies in this area will help to clarify the various cell signaling pathways that play an essential role in the process of adult lung growth.
An important question is whether the results observed in the immature recipients can be extrapolated to adults. We now know that adult lung can be induced to grow by two means, compensatory growth after lobectomy or pneumonectomy and transplantation into an immature recipient. The ultimate goal of this research, in terms of clinical application, is to be able to induce an adult lung to grow in a rapid, healthy manner without surgery. To do this we must discover the mechanisms that trigger and mediate adult lung growth (either after lobectomy or after transplantation into an immature recipient). This has potential therapeutic benefits for both adult and pediatric patients with lung disease or lung injury.
| Appendix: Discussion |
|---|
|
|
|---|
Dr Kaza. No, we have not looked at the contralateral lung in these experiments.
Dr Reardon. It would be interesting in your lung transplantation group to see what is happening in the contralateral lung.
Dr Frank W. Sellke (Boston, Mass). Why did you concentrate on the EGF rather than several other growth factors?
Dr Kaza. We could have investigated various growth factors, but our laboratory has been looking at EGFR expression because we believe that EGF is one of the growth factors that is central to this whole process of pulmonary morphogenesis. We are in the process of doing gene array to look at a wide variety of genes and their receptors to see whether they are upwardly regulated. We chose to investigate the expression of EGFR for these particular experiments, but we are going to investigate other growth factors in the future.
Dr Sellke. Do you have any idea as to what is the inciting influence that causes the increased expression of the growth factor?
Dr Kaza. We believe that it is a humoral response in relation to a transient hypoxia that occurs after both lobectomy and transplantation. When you remove the lobe or lung, the transient hypoxia results in a humoral response that upwardly regulates EGFR expression.
Sir Magdi Yacoub (Middlesex, United Kingdom). Have you looked at the expression of retinoic acid receptor, because that has been implicated in alveolar lung growth?
Dr Kaza. We have not looked at the retinoic acid receptor in these experiments. However, we have recently published data showing that retinoic acid does enhance compensatory lung growth through the upward regulation of EGFR (Kaza AK, Kron IL, Kern JA, Long SM, Fiser SM, Nguyen RP, Tribble CG, et al. Retinoic acid enhances lung growth after pneumonectomy. Ann Thorac Surg. 2001;71:1645-50).
Dr Raphael Bueno (Boston, Mass). Do you have any thoughts as to which cells are proliferating and in the posttransplantation situation; that is, whether they are the donor or the recipient cells?
Dr Kaza. With our immunohistochemical techniques we stain all the cells that are in the lung, but when we analyze the CPI we try to limit our count to the pneumocytes that are proliferating in the transplanted lung. Because we limit our analyses to the transplanted lung, we can say that this response is being measured in the donor cells.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
, and localization of their common receptor in fetal human lung development. Pediatr Res. 1996;39:448-55.[Medline]This article has been cited by other articles:
![]() |
C. S. Rogers, W. M. Abraham, K. A. Brogden, J. F. Engelhardt, J. T. Fisher, P. B. McCray Jr., G. McLennan, D. K. Meyerholz, E. Namati, L. S. Ostedgaard, et al. The porcine lung as a potential model for cystic fibrosis Am J Physiol Lung Cell Mol Physiol, August 1, 2008; 295(2): L240 - L263. [Abstract] [Full Text] [PDF] |
||||
![]() |
Mechanisms and Limits of Induced Postnatal Lung Growth Am. J. Respir. Crit. Care Med., August 1, 2004; 170(3): 319 - 343. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |